Description: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network.
Home Page: www.wuxibiologics.com
No. 108, Meiliang Road
Wuxi,
214092
China
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Ge Li Ph.D. | Founder & Chairman |
| Dr. Zhisheng Chen Ph.D. | CEO & Executive Director |
| Dr. Weichang Zhou Ph.D. | Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director |
| Mr. Ming Tu | CFO & Executive VP |
| Lihua Yu M.B.A. | COO & Senior VP |
| Dr. Sherry Gu Ph.D. | Chief Technology Officer and Executive VP of Global Biologics Development Department |
| Dr. Jijie Gu Ph.D. | Chief Scientific Officer & President of Global Biologics Research |
| Ms. Lina Fan Ph.D. | Senior VP & Head of Investor Relations |
| He Wang | Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management |
| Ms. Li Xiong | VP & Head of Global Human Resources |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 15.1976 |
|---|---|
| Trailing PE: | 26.6471 |
| Price-to-Book MRQ: | 1.6622 |
| Price-to-Sales TTM: | 0.5624 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12435 |